CHICAGO - More bad news for CytRx (CYTR) at the American Society of Clinical Oncology annual meeting.

Results from the phase III study of CytRx's aldoxorubicin in front-line sarcoma patients were presented on Friday. The company had previously acknowledged aldoxorubicin's failure to significantly prolong progression-free survival, the study's primary endpoint. 

But what about survival? Maybe aldoxorubicin is helping sarcoma patients live longer? 

No, it is not. 

Read More Trending Articles:

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

Famed Chartist Marc Chaikin Gives Jim Cramer His Top Picks This Wednesday

Famed Chartist Marc Chaikin Gives Jim Cramer His Top Picks This Wednesday

Rewind: Jim Cramer on Trade, Pepsico, SodaStream, Estee Lauder and Nike

Rewind: Jim Cramer on Trade, Pepsico, SodaStream, Estee Lauder and Nike

Here's Why Sears Stock Got Slammed Again

Here's Why Sears Stock Got Slammed Again

Tesla's Suppliers Worry About Whether They'll Be Paid

Tesla's Suppliers Worry About Whether They'll Be Paid

Dow Leads Gains as Stocks End Higher

Dow Leads Gains as Stocks End Higher